After showing, by comparing previously deposited MeRIP-seq data of one glioma stem cell line and neural progenitor cells, that the two cell types were clearly distinct from the point of view of m6A RNA methylation, these authors also evidenced a significantly higher expression of METTL3 and YTHDF2, at both the mRNA and the protein levels, in GBM patients’ samples compared to normal brain controls, and highlighted that METTL3 and YTHDF2 expression negatively correlated with patient survival. The gene discussed is METTL3; the disease is central nervous system cancer.